Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia

Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia: Redefining Early Urate Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02502565

Enrollment

150

Registered

2015-07-20

Start date

2012-01-31

Completion date

2019-03-31

Last updated

2018-06-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Brief summary

An observational study to evaluate the prevalence of US changes of gout in the joints and tendons of patients with different degrees of asymptomatic hyperuricemia. The investigators' findings may support the extension of the spectrum of urate disease, and define a subset of patients that may benefit from early urate-lowering therapy.

Interventions

OTHERUric acid level

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Patients must have at least one serum uric acid level l ≥ 7.0 mg/dL within the last two years without a clinical diagnosis of gout per American College of Rheumatology criteria30 (appendix A). 2. Patients, of matched gender and age, with normal uric acid levels will serve as controls.

Exclusion criteria

1. Patients who meet or have met the ACR criteria for Gout, unable to read English, and/or have terminal illness will not be eligible to participate in the study. 2. Patients with a diagnosis of skin psoriasis31, rheumatoid arthritis, or spondyloarthropathies will not be eligible to participate. 3. Patients who are on urate-lowering therapy. 4. Patients with 1 or 2 total knee replacements.

Design outcomes

Primary

Measure	Time frame
Number of Urate Depositions Detected in Ultrasound	2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026